Evidence map›Paper›PMID 30214193›Full record

ArticleInternational journal of nanomedicine2018

Anticancer activity of paclitaxel-loaded keratin nanoparticles in two-dimensional and perfused three-dimensional breast cancer models.

Federica Foglietta, Giulio C Spagnoli, Manuele Giuseppe Muraro, Marco Ballestri, Andrea Guerrini, Claudia Ferroni, Annalisa Aluigi, Giovanna Sotgiu, Greta Varchi

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Federica FogliettaDepartment of Drug Science & Technology, University of Torino, Torino, Italy.
Giulio C SpagnoliDepartment of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland, gcspagnoli@gmail.com.
Manuele Giuseppe MuraroDepartment of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland, gcspagnoli@gmail.com.
Marco BallestriInstitute for Organic Synthesis & Photoreactivity, National Research Council, Bologna, Italy, greta.varchi@isof.cnr.it.
Andrea GuerriniInstitute for Organic Synthesis & Photoreactivity, National Research Council, Bologna, Italy, greta.varchi@isof.cnr.it.
Claudia FerroniInstitute for Organic Synthesis & Photoreactivity, National Research Council, Bologna, Italy, greta.varchi@isof.cnr.it.
Annalisa AluigiInstitute for Organic Synthesis & Photoreactivity, National Research Council, Bologna, Italy, greta.varchi@isof.cnr.it.
Giovanna SotgiuInstitute for Organic Synthesis & Photoreactivity, National Research Council, Bologna, Italy, greta.varchi@isof.cnr.it.
Greta VarchiInstitute for Organic Synthesis & Photoreactivity, National Research Council, Bologna, Italy, greta.varchi@isof.cnr.it.
Institute of Organic Synthesis and Photoreactivity · ITUniversity Hospital of Basel · CHUniversity of Basel · CHUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTaxanes are highly effective cytotoxic drugs for progressing breast cancer treatment. However, their poor solubility and high toxicity urge the development of innovative formulations of potential clinical relevance. MATERIALS AND

methodsBy using a simple and straightforward aggregation method, we have generated paclitaxel (PTX) loaded in keratin nanoparticles (KER-NPs-PTX). Their activities were tested against human breast cancer MCF-7 and MDA MB 231 cell lines in conventional two-dimensional (2D) cultures and in a dynamic three-dimensional (3D) model with perfused bioreactor (p3D). Moreover, KER-NPs-PTX activity was compared to free PTX and to PTX loaded in albumin nanoparticles (HSA-NPs-PTX). Cell viability, induction of apoptosis, and gene expression analysis were used as readouts.

resultsIn 2D cultures, KER-NPs-PTX was able to inhibit tumor cell viability and to induce apoptosis similarly to PTX and HSA-NPs-PTX. In the p3D model, a lower sensitivity of tumor cells to treatments was observed. Importantly, only KER-NPs-PTX was able to induce a statistically significant increase in apoptotic cell percentages following 24 h treatment for MCF-7 (16.7±4.0 early and 11.3±4.9 late apoptotic cells) and 48 h treatment for MDA MB 231 (21.3±11.2 early and 10.5±1.8 late apoptotic cells) cells. These effects were supported, at least for MCF-7 cells, by significant increases in the expression of proapoptotic

conclusionKER-NPs-PTX, generated by a simple procedure, is characterized by high water solubility and enhanced PTX-loading ability, as compared to HSA-NPs-PTX. Most importantly, it appears to be able to exert effective anticancer activities on breast cancer cells cultured in 2D or in p3D models.

Indexed as

Models, BiologicalAnimalsAntineoplastic Agents, PhytogenicApoptosisBreast NeoplasmsCell SurvivalDrug LiberationFemaleGene Expression Regulation, NeoplasticHumansKeratinsMCF-7 CellsNanoparticlesPaclitaxelAntineoplastic Agents, PhytogenicKeratinsPaclitaxelbreast cancerkeratinnanoparticlespaclitaxelperfused three-dimensional models

Identifiers

PMID30214193
PMCPMC6122896
OpenAlexW2889309246

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.